DDInter107 DDInter1016
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements. It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors. In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or. Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Apalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eplerenone
Apalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Polatuzumab vedotin
Apalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anisindione
Apalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Delafloxacin
Apalutamide {u} may lead to a major life threatening interaction when taken with {v} Isavuconazonium
Apalutamide {u} may lead to a major life threatening interaction when taken with {v} Abemaciclib
Apalutamide may cause a minor interaction that can limit clinical effects when taken with Eplerenone
Apalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Apalutamide may lead to a major life threatening interaction when taken with Isavuconazonium
Apalutamide may lead to a major life threatening interaction when taken with Abemaciclib